The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Cost to Medicare from bone modifying agent overuse in castration-sensitive prostate cancer.
 
Aaron Philip Mitchell
No Relationships to Disclose
 
Nirjhar Chakraborty
No Relationships to Disclose
 
David Nemirovsky
No Relationships to Disclose
 
Akriti Mishra Meza
Stock and Other Ownership Interests - DNA Therapeutics; Johnson & Johnson; Teladoc
 
Sonia Persaud
No Relationships to Disclose
 
Azeez Farooki
Leadership - Novartis
Consulting or Advisory Role - Amgen; Novartis
 
Michael J. Morris
Stock and Other Ownership Interests - Doximity
Consulting or Advisory Role - Amgen; AstraZeneca; Blue Earth Diagnostics; Clarity Pharmaceuticals; Convergent Therapeutics; Daiichi; ITM Isotope Technologies Munich; Lantheus Medical Imaging; Pfizer; POINT Biopharma; Progenics; Telix Pharmaceuticals; Z-Alpha
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Celgene (Inst); Corcept Therapeutics (Inst); Janssen (Inst); Novartis (Inst); Progenics (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - APCCC; AstraZeneca; Memorial Sloan-Kettering Cancer Center
(OPTIONAL) Uncompensated Relationships - Bayer; Janssen Oncology; Novartis